Funding newsPublished October 15, 2026

INGENIA Therapeutics Raises $43.0M to Advance Therapeutic Antibodies

Recently funded · $43.0M UnknownManufacturingUSView source

Get the full INGENIA Therapeutics company profile

Access contacts, investors, buying signals & more

INGENIA Therapeutics has raised $43.0M to develop therapeutic antibodies aimed at restoring dysfunctional microvessels to a healthy state.

The Watertown, MA-based biotech is pursuing treatments across multiple ophthalmic and systemic diseases, betting that repairing the tiny blood vessels underlying those conditions can yield durable, best-in-class therapies. The company did not disclose the round type or its investors.

From the source

Sven

🚀 Ophthalmology Biotech Funding in Q3 2026: TED Is Hot!🔥 A little later than usual with my quarterly funding update, as EURETINA/AAO kept me busy over the past weeks! Following a record-breaking Q2, investment in ophthalmology remained strong in Q3.

This quarter revealed some interesting trends, particularly in Thyroid Eye Disease, gene therapy commercialization, and the continued reopening of the IPO market. 🥇 Thyroid Eye Disease Takes Center Stage ▪️ Yarrow Bioscience: ~$162M net public offering for its anti-TSHR antibody program. ▪️ Sling Therapeutics: $123M Series C for linsitinib, an oral TED treatment. ▪️ Khartis Therapeutics: $50M S

Unlock the full source

CEO quotes, investor details and growth metrics

Start free trial

Other United States companies recently funded

View all

Leaven Foods
A 2026 NEXTY Award winner for “Best Pantry Staple” at the prestigious Natural Products Expo, Leaven’s "Instant Sourdough" is the first and only real sourdough starter replacement that eliminates the need for a traditional sourdough starter for commercial and home bakers. Made from carefully curated wild yeast and beneficial bacteria isolated from sourdough, it delivers real sourdough fermentation, flavor and benefits in a convenient powdered format. Bakers simply mix it into the dough; allow it to rise, ferment, and then bake. No starter required. In addition, Leaven offers an Instant Wild Yeast, a premium baking yeast for better baking performance. It’s an undomesticated wild yeast that delivers a rich, buttery flavor creating delicious bread the way it's meant to taste. Both products are all natural, non-GMO and gluten-free. Founded by microbiologists with a passion for baking, Leaven Foods, harnesses the microbial power of ancient fermentations to create all-natural, flavorful, healthier, and more sustainable food. At the heart of Leaven Foods is a proprietary fermentation platform designed to understand and preserve the complex microbial ecosystems that make wild fermentation so unique. With 1/3 of food fermented, the mission is bigger than sourdough. Leaven will bring the complexity, flavor and potential benefits of naturally fermented foods to the masses. Leaven is building a new generation of fermentation ingredients and applications, starting with sourdough and expanding into other baked goods and fermented foods. By combining microbiology, computational biology and food science, Leaven is making wild fermentation more accessible, convenient and scalable, without compromising what makes it special.
$2.0M Seed

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#	Company	Round	Amount	Date
1	Shockwave Medical United States	Unknown	$13.1B	2y ago
2	NeuroEM Therapeutics United States	Unknown

Other recent Unknown rounds

Companies that recently closed a Unknown round.

#	Company	Round	Amount	Date
1	Spout Finance	Unknown	$2.0M	today
2	Galvmac Ltd United Kingdom	Unknown	$396.7K	today

INGENIA Therapeutics Raises $43.0M to Advance Therapeutic Antibodies

From the source

Other United States companies recently funded

Biggest recent Biotechnology rounds

Other recent Unknown rounds

Unlock INGENIA Therapeutics's full profile

Investors

Similar recently funded companies